Viehweger Florian, Hoop Jennifer, Tinger Lisa-Marie, Bernreuther Christian, Büscheck Franziska, Clauditz Till S, Hinsch Andrea, Jacobsen Frank, Luebke Andreas M, Steurer Stefan, Hube-Magg Claudia, Kluth Martina, Marx Andreas H, Krech Till, Lebok Patrick, Fraune Christoph, Burandt Eike, Sauter Guido, Simon Ronald, Minner Sarah
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Pathologie-Hamburg, Labor Lademannbogen Medizinisches Versorgungszentrum (MVZ) GmbH, 22339 Hamburg, Germany.
Biomedicines. 2024 Apr 25;12(5):957. doi: 10.3390/biomedicines12050957.
Androgen receptor (AR) is a transcription factor expressed in various normal tissues and is a therapeutic target for prostate and possibly other cancers. A TMA containing 18,234 samples from 141 different tumor types/subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. AR positivity was found in 116 tumor types including 66 tumor types (46.8%) with ≥1 strongly positive tumor. Moderate/strong AR positivity was detected in testicular sex cord-stromal tumors (93.3-100%) and neoplasms of the prostate (79.3-98.7%), breast (25.0-75.5%), other gynecological tumors (0.9-100%), kidney (5.0-44.1%), and urinary bladder (5.4-24.2%). Low AR staining was associated with advanced tumor stage (pTa versus pT2-4; < 0.0001) in urothelial carcinoma; advanced pT ( < 0.0001), high tumor grade ( < 0.0001), nodal metastasis ( < 0.0001), and reduced survival ( = 0.0024) in invasive breast carcinoma; high pT ( < 0.0001) and grade ( < 0.0001) in clear cell renal cell carcinoma (RCC); and high pT ( = 0.0055) as well as high grade ( < 0.05) in papillary RCC. AR staining was unrelated to histopathological/clinical features in 157 endometrial carcinomas and in 221 ovarian carcinomas. Our data suggest a limited role of AR immunohistochemistry for tumor distinction and a prognostic role in breast and clear cell RCC and highlight tumor entities that might benefit from AR-targeted therapy.
雄激素受体（AR）是一种在多种正常组织中表达的转录因子，是前列腺癌以及可能的其他癌症的治疗靶点。通过免疫组织化学分析了一个组织微阵列（TMA），该TMA包含来自141种不同肿瘤类型/亚型的18234个样本以及76种不同正常组织类型的608个样本。在116种肿瘤类型中发现了AR阳性，其中包括66种肿瘤类型（46.8%）有≥1个强阳性肿瘤。在睾丸性索间质肿瘤（93.3 - 100%）、前列腺肿瘤（79.3 - 98.7%）、乳腺肿瘤（25.0 - 75.5%）、其他妇科肿瘤（0.9 - 100%）、肾脏肿瘤（5.0 - 44.1%）和膀胱肿瘤（5.4 - 24.2%）中检测到中度/强AR阳性。在尿路上皮癌中，低AR染色与肿瘤晚期（pTa与pT2 - 4相比；<0.0001）相关；在浸润性乳腺癌中，与晚期pT（<0.0001）、高肿瘤分级（<0.0001）、淋巴结转移（<0.0001）及生存率降低（=0.0024）相关；在透明细胞肾细胞癌（RCC）中，与高pT（<0.0001）和分级（<0.0001）相关；在乳头状RCC中，与高pT（=0.0055）以及高分级（<0.05）相关。在157例子宫内膜癌和221例卵巢癌中，AR染色与组织病理学/临床特征无关。我们的数据表明AR免疫组织化学在肿瘤鉴别中的作用有限，而在乳腺癌和透明细胞RCC中有预后作用，并突出了可能从AR靶向治疗中获益的肿瘤实体。
